Steve Pakola - 02 Jul 2026 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Reporting relationship: Chief Medical Officer
Issuer ticker: RGNX
Reported as of: 02 Jul 2026
Net transaction value: -$29,476
SEC form: 4
Accepted by SEC: 06 Jul 2026, 16:51:18 UTC
Prior SEC filing: 01 Jul 2026
Next SEC filing: 04 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Patrick J. Christmas as attorney-in-fact

Key filing fact

Steve Pakola filed Form 4 for REGENXBIO Inc. (RGNX) on 06 Jul 2026.

Key facts

This page summarizes Steve Pakola's Form 4 filing for REGENXBIO Inc. (RGNX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jul 2026, 16:51.

Change

Previous filing in this sequence was filed on 01 Jul 2026.
Current net transaction value: -$29,476.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001700659 Primary reporting owner

PAKOLA STEVE

Relationship: Chief Medical Officer
Address: C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE
Signature: /s/ Patrick J. Christmas as attorney-in-fact
Signature date: 06 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RGNX transaction

Common Stock

Options Exercise

Transaction value
Shares: +2,161
Change %: +1%
Price: $7.86^*
Shares after: 215,170
Date: 02 Jul 2026
Ownership: Direct
Footnotes: F1

RGNX transaction

Common Stock

Sale

Transaction value: $29,476
Shares: -2,161
Change %: -1%
Price: $13.64
Shares after: 213,009
Date: 02 Jul 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RGNX transaction Derivative

Stock Options (Right to Buy)

Options Exercise

Transaction value
Shares: -2,161
Change %: -3.2%
Price: $0.000000^*
Shares after: 64,812
Date: 02 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,161
Exercise price: $7.86
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

This transaction was effected pursuant to a Rule 10b5-1 trading plan.

Footnote F2

The previously granted option, representing a right to purchase a total of 103,698 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 2, 2026, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.